Yuhan recently handed out gold rings to former employees, showing Leclaza (Lazertinib)'s commitment to success.

According to the industry on the 11th, Yuhan provided a gold ring with LECLAZA to all employees at the end of last February. It was only a month after receiving Conditional Marketing Authorization (CMA) as the 31st Korean drug on January 18th.

Yuhan's officials congratulated Leclaza for permission and wished for success in the future. An official from Yuhan said, "A ring was distributed in commemoration of the achievement of the long-aspired work." He wished the success of Leclaza and gave the entire temple a gold ring.
Immediately after CMA earlier this year, a gold ring